Your browser doesn't support javascript.
loading
Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment.
Cancello, Raffaella; Brunani, Amelia; Brenna, Ettore; Soranna, Davide; Bertoli, Simona; Zambon, Antonella; Lukaski, Henry C; Capodaglio, Paolo.
Affiliation
  • Cancello R; Obesity Unit and Laboratory of Nutrition and Obesity Research, Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Brunani A; Laboratory of Biomechanics, Rehabilitation and Ergonomics, IRCCS, Istituto Auxologico Italiano, Piancavallo Verbania, Italy. brunani@auxologico.it.
  • Brenna E; Biostatistic Unit, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Soranna D; Biostatistic Unit, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Bertoli S; Obesity Unit and Laboratory of Nutrition and Obesity Research, Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Zambon A; Department of Food, Environmental and Nutritional Sciences (DeFENS), International Center for the Assessment of Nutritional Status (ICANS), University of Milan, Via Sandro Botticelli 21, 20133, Milan, Italy.
  • Lukaski HC; Biostatistic Unit, IRCCS Istituto Auxologico Italiano, Milano, Italy.
  • Capodaglio P; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
Rev Endocr Metab Disord ; 24(3): 451-464, 2023 06.
Article in En | MEDLINE | ID: mdl-36484943
ABSTRACT
Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability of the two measured parameters (resistance, R, and reactance, Xc) that contribute to the determination of PhA. Controversial is the relation between PhA and BMI that might vary with graded levels of obesity due to the variation in fat and free fat mass. Obesity is frequently associated with metabolic, hepatic, cardiovascular and kidney diseases that introduce variations in PhA values, in relation to multimorbidity and severity degree of these diseases. It is reported that the improvement of clinical condition is associated with a positive change in PhA. Also, the treatment of obesity with weight loss might confirm this effect, but with different responses in relation to the type and duration of the intervention applied. In fact, the effect appears not only related to the percentage of weight loss but also the possible loss of free fat mass and the nutritional, metabolic and structural modifications that might follow each therapeutic approach to decrease body weight. We can conclude that the PhA could be used as marker of health status in patients with obesity supporting an appropriate weight loss intervention to monitor efficacy and fat free mass preservation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Composition / Overweight Type of study: Diagnostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Rev Endocr Metab Disord Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2023 Document type: Article Affiliation country: Italia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Composition / Overweight Type of study: Diagnostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Rev Endocr Metab Disord Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2023 Document type: Article Affiliation country: Italia